You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Patient clinical characteristics (n = 28)

From: Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study

Characteristic No. of patients (%)
Mean age, years (SD) 63 (10)
Male sex 20 (71)
Cancer type
 Melanoma 7 (25)
 Renal cell carcinoma 4 (14)
 Prostate carcinoma 4 (14)
 Urothelial 3 (11)
 Other solid tumors 10 (36)
Cancer stage
 III 6 (21)
 IV 22 (79)
ICI type
 CTLA-4 8 (29)
 PD-1/L1 12 (43)
 Combination 8 (29)
Median no. of ICI infusions (IQR) 3 (1–36)
Median time to diarrhea onset, weeks (IQR) 10 (1–70)
Peak CTCAE grade of diarrhea
 2 15 (54)
 3–4 13 (46)
Peak CTCAE grade of colitis
 1–2 16 (57)
 3–4 12 (43)
Colitis symptoms
 Abdominal pain 14 (50)
 Blood or mucous in stool 11 (39)
Other adverse events
 Dermatological 4 (14)
 Endocrine 2 (7)
 Musculoskeletal 2 (7)
 Pulmonary 1 (4)
 Pancreatic 1 (4)
  1. Abbreviations: SD, standard deviation; ICI, immune checkpoint inhibitor; IQR, interquartile range; CTCAE, Common Terminology Criteria of Adverse Events